Drug-eluting stent, but not bare metal stent, accentuates the systematic inflammatory response in patients

Cardiology (Switzerland)

Volumn 128, Issue 3, 2014, Pages 259-265

  Liu, Junhui ^a   Zhuo, Xiao Zhen ^a   Liu, Weimin ^a   Wan, Zhaofei ^a   Wang, Xinhong ^a   Zhang, Weiping ^a   Gao, Shanshan ^a   Yuan, Zuyi ^a   Wu, Yue ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Drug eluting stent; Mononuclear cells; Patients; Pro inflammation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; EVEROLIMUS; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P50; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; RAPAMYCIN; GLUCOSE; LIPID;

ARTICLE; BARE METAL STENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HEART EJECTION FRACTION; HUMAN; METABOLIC PARAMETERS; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; CORONARY STENOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; RANDOMIZED CONTROLLED TRIAL; STENT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BINDING AFFINITY; INFLAMMATION;

ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; CORONARY STENOSIS; DRUG-ELUTING STENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-4; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MATRIX METALLOPROTEINASE 9; RNA, MESSENGER; SIROLIMUS; STENTS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900879534     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000358508     Document Type: Article

References (19)

1. Moses JW, Leon MB, Popma JJ, et al: Sirolim-us-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 3494:1315-1323.
2. Elabbassi W, Osman AN, Chowdhury MA, Nooryani AA: Device-related thrombus overlying a left-atrial occlusion device implanted for persistent spontaneous echo contrast despite prolonged oral anticoagulation therapy. Cardiology 2013; 125:78-81.
3. Wilson GJ, Nakazawa G, Schwartz RS, et al: Comparison of inflammatory response after implantation of sirolimus-and paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009; 120:141-149.
4. Nakazawa G, Finn AV, Vorpahl M, et al: Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus-and paclitaxel-eluting stents. J Am Coll Cardiol 2011; 57:390-398.
5. Huang SS, Huang PH, Leu HB, et al: Serum bilirubin predicts long-term clinical outcomes in patients with cardiac syndrome X. Heart 2010; 96:1227-1232.
6. Ghanim H, Aljada A, Hofmeyer D, et al: Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004; 110:1564-1571.
7. Uribarri J, Cai W, Ramdas M, et al: Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011; 34:1610-1616.
8. Wu Y, Zhang W, Liu W, et al: The double-faced metabolic and inflammatory effects of standard drug therapy in patients after percutaneous treatment with drug-eluting stent. Atherosclerosis 2011; 215:170-175.
9. Goldberg A, Zinder O, Zdorovyak A, Diamond E, Lischinsky S, Gruberg L, et al: Diagnostic coronary angiography induces a systemic inflammatory response in patients with stable angina. Am Heart J 2003; 146: 819-823.
10. Ramadan MM, Kodama M, Mitsuma W, Ito M, Kashimura T, Ikrar T, et al: Impact of percutaneous coronary intervention on the levels of interleukin-6 and C-reactive protein in the coronary circulation of subjects with coronary artery disease. Am J Cardiol 2006; 98: 915-917.
11. Xue JH, Yuan Z, Wu Y, et al: High glucose promotes intracellular lipid accumulation in vascular smooth muscle cells by impairing cholesterol influx and efflux balance. Cardio-vasc Res 2010; 86:141-150.
12. Anderson JL, Adams CD, Antman EM, et al: 2011 ACCF/AHA Focused Update Incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:e426-e579.
13. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P: Inflammatory cyto-kines in heart failure: mediators and markers. Cardiology 2012; 122:23-35.
14. Miller M, DiNicolantonio JJ, Can M, Grice R, Damoulakis A, Serebruany VL: The effects of ezetimibe/simvastatin versus simvastatin monotherapy on platelet and inflammatory biomarkers in patients with metabolic syndrome. Cardiology 2013; 125:74-77.
15. Baker RG, Hayden MS, Ghosh S: NF-κB, inflammation, and metabolic disease. Cell Metab 2011; 13: 11-22.
16. Hayden MS, Ghosh S: NF-κB in immunobiol-ogy. Cell Res 2011; 21:223-244.
17. Hayden MS, Ghosh S: NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012; 26:203-234.
18. Shen Y, Yuan Z, Yin A, et al: Antiatherogenic effect of pioglitazone on uremic apolipopro-tein E knockout mice by modulation of the balance of regulatory and effector T cells. Atherosclerosis 2011; 218:330-338.
19. Duan SZ, Usher MG, Mortensen RM: Per-oxisome proliferator-activated receptor-γ-mediated effects in the vasculature. Circ Res 2008; 102: 283-294.